

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Suvaxyn Circo emulsion for injection for pigs

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 2 ml dose contains:

Active substance:

Inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 ORF2 protein

2.3 – 12.4 RP*

*Relative potency units determined by ELISA antigen quantification (*in vitro* potency test) compared to a reference vaccine.

Adjuvant:

MetaStim containing:

Squalane

8 µl (0.4% v/v)

Poloxamer 401

4 µl (0.2% v/v)

Polysorbate 80

0.64 µl (0.032% v/v)

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Thiomersal	0.2 mg
Monobasic potassium phosphate anhydrous	
Sodium chloride	
Potassium chloride	
Disodium phosphate anhydrous	
Sodium phosphate dibasic heptahydrate	
Disodium tetraborate decahydrate	
EDTA tetrasodium	
Water for injections	

White homogenous emulsion.

A slight black deposit may appear and the emulsion may separate into two distinct phases during storage. Upon shaking, the black deposit disappears and the emulsion becomes homogenous again.

3. CLINICAL INFORMATION

3.1 Target species

Pigs (for fattening).

3.2 Indications for use for each target species

For active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (PCV2) to reduce viral load in blood and lymphoid tissues and faecal shedding caused by infection with PCV2.

Onset of immunity: 3 weeks.

Duration of immunity: 23 weeks.

3.3 Contraindications

None.

3.4 Special warnings

Vaccinate healthy animals only.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Pigs (for fattening):

Very common (>1 animal / 10 animals treated):	Elevated temperature ¹ Injection site inflammation ² , Injection site pain ³ , injection site reddening ³ , injection site swelling ³
Uncommon (1 to 10 animals / 1,000 animals treated):	Hypersensitivity reactions (e.g. depression, diarrhoea or vomiting) ⁴
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Anaphylaxis ⁵

¹Transient; observed during the first 24 hours after vaccination. On average 1 °C but may exceed 2°C in individual pigs. This resolves spontaneously within 48 hours without treatment.

²Post-mortem examination of the injection site, performed 4 weeks after the administration of a repeated single dose of the vaccine, very commonly revealed a mild lymphocytic-granulomatous inflammatory response.

³The area of local tissue reactions is in general below 2 cm in diameter and may last up to 2 days.

⁴Normally resolve without treatment.

⁵In case of such reactions, appropriate treatment is recommended.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

The safety of the veterinary medicinal product has not been established during pregnancy or lactation.

Pregnancy and lactation:

Do not use during pregnancy and lactation.

Fertility:

No information is available on the safety of this vaccine in breeding boars. Do not use in breeding boars.

3.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

3.9 Administration routes and dosage

Intramuscular use.

Administer one dose of 2 ml to pigs in the neck behind the ear.

Vaccination schedule:

One injection from 3 weeks of age.

Shake well before administration and intermittently during the process of vaccination.

The use of a multi-dosing syringe is recommended. Use vaccination devices according to the manufacturer's instructions. The vaccine is to be administered aseptically.

During storage, a slight black deposit may appear and the emulsion may separate into two distinct phases.

Upon shaking, the black deposit disappears and the emulsion becomes homogenous again.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

A transient increase in body temperature (on average 0.8 °C) was observed 4 hours after administration of a 2-fold overdose. This resolved spontaneously within 24 hours without treatment. Local tissue reaction in the form of swelling (below 2 cm in diameter) at the injection site was commonly observed and resolved within 2 days.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Zero days.

4. IMMUNOLOGICAL INFORMATION

4.1 ATCvet code: QI09AA07

The vaccine contains an inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 ORF2 protein. It is intended to stimulate active immunity against PCV2 in pigs.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Do not mix with any other veterinary medicinal product.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 18 months.
Shelf life after first opening the immediate packaging: use immediately.

5.3 Special precautions for storage

Store and transport refrigerated (2 °C – 8 °C).
Do not freeze.
Protect from light.

5.4 Nature and composition of immediate packaging

High density polyethylene vials of 50 ml, of 100 ml and of 250 ml (25, 50 and 125 doses), with a chlorobutyl elastomer closure and sealed with an aluminium cap.

Cardboard box of 1 vial of 50 ml (25 doses), 100 ml (50 doses) or 250 ml (125 doses).
Cardboard box of 10 vials of 50 ml (25 doses) or 100 ml (50 doses).
Cardboard box of 4 vials of 250 ml (125 doses).

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

Zoetis Belgium

7. MARKETING AUTHORISATION NUMBER(S)

EU/2/17/223/001-006

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: 07/02/2018.

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

{DD/MM/YYYY}

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

ANNEX II

OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

None.

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE**Cardboard box****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Suvaxyn Circo emulsion for injection

2. STATEMENT OF ACTIVE SUBSTANCES

Each 2 ml dose contains:

Inactivated recombinant chimeric porcine circovirus type 1 containing the
porcine circovirus type 2 ORF2 protein

2.3-12.4 RP

3. PACKAGE SIZE

1 x 50 ml (25 doses)

1 x 100 ml (50 doses)

1 x 250 ml (125 doses)

10 x 50 ml (25 doses)

10 x 100 ml (50 doses)

4 x 250 ml (125 doses)

4. TARGET SPECIES

Pigs (for fattening).

5. INDICATIONS**6. ROUTES OF ADMINISTRATION**

Intramuscular use.

7. WITHDRAWAL PERIODS

Withdrawal period: Zero days.

8. EXPIRY DATE

Exp. {mm/yyyy}

Once broached use immediately.

9. SPECIAL STORAGE PRECAUTIONS

Store and transport refrigerated.
Do not freeze.
Protect from light.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”
--

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”
--

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”
--

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Zoetis Belgium

14. MARKETING AUTHORISATION NUMBERS
--

EU/2/17/223/001 (1 x 50 ml)
EU/2/17/223/002 (1 x 100 ml)
EU/2/17/223/003 (1 x 250 ml)
EU/2/17/223/004 (10 x 50 ml)
EU/2/17/223/005 (10 x 100 ml)
EU/2/17/223/006 (4 x 250 ml)

15. BATCH NUMBER

Lot {number}

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE**HDPE vials (125 doses)****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Suvaxyn Circo emulsion for injection.

**2. STATEMENT OF ACTIVE SUBSTANCES**

Each 2 ml dose contains:

Inactivated recombinant chimeric PCV type 1 containing the PCV type 2 ORF2 protein 2.3-12.4 RP

3. TARGET SPECIES

Pigs (for fattening).

4. ROUTES OF ADMINISTRATION

IM

Read the package leaflet before use.

5. WITHDRAWAL PERIODS

Withdrawal period: Zero days.

6. EXPIRY DATE

Exp. {mm/yyyy}

Once broached use immediately.

7. SPECIAL STORAGE PRECAUTIONS

Store and transport refrigerated.

Do not freeze.

Protect from light.

8. NAME OF THE MARKETING AUTHORISATION HOLDER

Zoetis Belgium

9. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**HDPE vials (25 or 50 doses)****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Suvaxyn Circo

**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

Inactivated recombinant chimeric PCV type 1 containing the PCV type 2 ORF2 protein 2.3-12.4 RP

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp.{mm/yyyy}

Once broached use immediately.

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Suvaxyn Circo emulsion for injection for pigs

2. Composition

Each 2 ml dose contains:

Active substance:

Inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 ORF2 protein

2.3 – 12.4 RP*

*Relative potency units determined by ELISA antigen quantification (*in vitro* potency test) compared to a reference vaccine.

Adjuvant:

MetaStim containing:

Squalane

8 µl (0.4% v/v)

Poloxamer 401

4 µl (0.2% v/v)

Polysorbate 80

0.64 µl (0.032% v/v)

Excipient:

Thiomersal

0.2 mg

White homogenous emulsion.

A slight black deposit may appear and the emulsion may separate into two distinct phases during storage. Upon shaking, the black deposit disappears and the emulsion becomes homogenous again.

3. Target species

Pigs (for fattening).

4. Indications for use

For active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (PCV2) to reduce viral load in blood and lymphoid tissues and faecal shedding caused by infection with PCV2.

Onset of immunity: 3 weeks.

Duration of immunity: 23 weeks.

5. Contraindications

None.

6. Special warnings

Special warnings:

Vaccinate healthy animals only.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Pregnancy and lactation:

The safety of the veterinary medicinal product has not been established during pregnancy or lactation.

Do not use during pregnancy and lactation.

Fertility:

No information is available on the safety of this vaccine in breeding boars. Do not use in breeding boars.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose:

A transient increase in body temperature (on average 0.8 °C) was observed 4 hours after administration of a 2-fold overdose. This resolved spontaneously within 24 hours without treatment. Local tissue reaction in the form of swelling (below 2 cm in diameter) at the injection site was commonly observed and resolved within 2 days.

Major incompatibilities:

Do not mix with any other veterinary medicinal product.

7. Adverse events

Pigs (for fattening):

Very common (>1 animal / 10 animals treated):	Elevated temperature ¹ Injection site inflammation ² , Injection site pain ³ , injection site reddening ³ , injection site swelling ³
Uncommon (1 to 10 animals / 1,000 animals treated):	Hypersensitivity reactions (e.g. depression, diarrhoea or vomiting) ⁴
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Anaphylaxis (severe allergic reaction) ⁵

¹Transient; observed during the first 24 hours after vaccination. On average 1 °C but may exceed 2 °C in individual pigs. This resolves spontaneously within 48 hours without treatment.

²Post-mortem examination of the injection site, performed 4 weeks after the administration of a repeated single dose of the vaccine, very commonly revealed a mild lymphocytic-granulomatous inflammatory response.

³The area of local tissue reactions is in general below 2 cm in diameter and may last up to 2 days.

⁴Normally resolve without treatment.

⁵In case of such reactions, appropriate treatment is recommended.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}.

8. Dosage for each species, routes and method of administration

Intramuscular use.

Single intramuscular injection in the neck behind the ear of one dose (2 ml) to pigs from 3 weeks of age.

9. Advice on correct administration

Shake well before administration and intermittently during the process of vaccination.

The vaccine is to be administered aseptically.

The use of a multi-dosing syringe is recommended. Use vaccination devices according to the manufacturer's instructions.

A slight black deposit may appear and the emulsion may separate into two distinct phases during storage. Upon shaking, the black deposit disappears and the emulsion becomes homogenous again.

10. Withdrawal periods

Zero days.

11. Special storage precautions

Keep out of the sight and reach of children.

Store and transport refrigerated (2 °C – 8 °C).

Do not freeze.

Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and the vial after Exp. The expiry date refers to the last day of that month.

Shelf life after first opening the immediate packaging: use immediately.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

EU/2/17/223/001-006.

Cardboard box of 1 vial of 50 ml (25 doses), 100 ml (50 doses) or 250 ml (125 doses).

Cardboard box of 10 vials of 50 ml (25 doses) or 100 ml (50 doses).

Cardboard box of 4 vials of 250 ml (125 doses).

Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

{DD/MM/YYYY}

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release:

Zoetis Belgium

Rue Laid Burniat 1

1348 Louvain-La-Neuve

Belgium

Local representatives and contact details to report suspected adverse reactions:

België/Belgique/Belgien

Zoetis Belgium

Mercuriusstraat 20

BE-1930 Zaventem

Tél/Tel: +32 (0) 800 99 189

Lietuva

Zoetis Belgium

Mercuriusstraat 20

1930 Zaventem

Belgija

Tel: +370 610 05088

Република България

Zoetis Belgium

Rue Laid Burniat 1

1348 Louvain-La-Neuve

Белгия

Тел: +359 888 51 30 30

Luxembourg/Luxemburg

Zoetis Belgium

Mercuriusstraat 20

1930 Zaventem

Belsch

Tél/Tel: +32 (2) 746 80 11

Česká republika

Zoetis Česká republika, s.r.o.

náměstí 14. října 642/17

CZ 150 00 Praha

Tel: +420 257 101 111

Magyarország

Zoetis Hungary Kft.

Csörsz u. 41.

HU-1124 Budapest

Tel.: +36 1 224 5200

Danmark

Zoetis Animal Health ApS
Øster Alle 48
DK-2100 København
Tlf: +45 70 20 73 05
adr.scandinavia@zoetis.com

Deutschland

Zoetis Deutschland GmbH
Schellingstr. 1
DE-10785 Berlin
Tel: +49 30 2020 0049
tierarzneimittelsicherheit@zoetis.com

Eesti

Zoetis Belgium
Mercuriusstraat 20
1930 Zaventem
Belgia
Tel: +370 610 05088

Ελλάδα

Zoetis Hellas S.A.
Φραγκοκκλησιάς 7, Μαρούσι
EL-15125 Αττική
Τηλ: +30 210 6791900

España

Zoetis Spain, S.L.
Parque Empresarial Vía Norte Edificio nº1,
c/ Quintanavides nº13
ES-28050 Madrid
Tel: +34 91 4191900

France

Zoetis France
10 rue Raymond David
FR-92240 Malakoff
Tél: +33 (0)800 73 00 65

Hrvatska

Zoetis B.V.
Podružnica Zagreb za promidžbu
Petra Hektorovića 2
HR-10000 Zagreb
Tel: +385 1 6441 462

Malta

Agrimed Limited
Mdina Road, Zebbug ZBG 9016,
MT
Tel: +356 21 465 797

Nederland

Zoetis B.V.
Rivium Westlaan 74
NL-2909 LD Capelle aan den IJssel
Tel: +31 (0)10 714 0900

Norge

Zoetis Animal Health ApS
Øster Alle 48
DK-2100 København
Danmark
Tlf: +47 23 29 86 80
adr.scandinavia@zoetis.com

Österreich

Zoetis Österreich GmbH
Floridsdorfer Hauptstr. 1
AT-1210 Wien
Tel: +43 (0)1 2701100 100
tierarzneimittelsicherheit@zoetis.com

Polska

Zoetis Polska Sp. z o.o.
ul. Postępu 17B
PL - 02-676 Warszawa
Tel.: +48 22 2234800

Portugal

Zoetis Portugal Lda.
Lagoas Park, Edifício 10
PT-2740-271 Porto Salvo
Tel: +351 21 042 72 00

România

Zoetis România S.R.L.
Expo Business Park, 54A Aviator Popișteanu,
Clădirea 2, Etaj 1-3, Sector 1,
București, 012095 - RO
Tel: +40785019479

Ireland

Zoetis Belgium S.A. (Irish Branch)
2nd Floor, Building 10,
Cherrywood Business Park,
Loughlinstown,
Co. Dublin,
IE – Dublin D18 T3Y1
Tel: +353 (0) 1 256 9800

Ísland

Zoetis Animal Health ApS
Øster Alle 48
DK-2100 København
Danmörku
Sími: +45 70 20 73 05
adr.scandinavia@zoetis.com

Italia

Zoetis Italia S.r.l.
Via Andrea Doria 41M,
IT-00192 Roma
Tel: +39 06 3366 8111

Κύπρος

Zoetis Hellas S.A.
Φραγκοκκλησιάς 7, Μαρούσι
15125, Αττική
Ελλάδα
Τηλ: +30 210 6791900

Latvija

Zoetis Belgium
Mercuriusstraat 20
1930 Zaventem
Belģija
Tel: +370 610 05088

Slovenija

Zoetis B.V.
Podružnica Zagreb za promidžbu
Petra Hektorovića 2,
10000 Zagreb,
Hrvaška
Tel: +385 1 6441 462

Slovenská republika

Zoetis Česká republika, s.r.o.
náměstí 14. října 642/17
150 00 Praha
Česká republika
Tel: +420 257 101 111

Suomi/Finland

Zoetis Finland Oy
Bulevardi 21 / SPACES
FI-00180 Helsinki/Helsingfors
Suomi/Finland
Puh/Tel: +358 10 336 7000
laaketurva@zoetis.com

Sverige

Zoetis Animal Health ApS
Øster Alle 48
DK-2100 Köpenhamn
Danmark
Tel: +46 (0) 76 760 0677
adr.scandinavia@zoetis.com

United Kingdom (Northern Ireland)

Zoetis Belgium S.A. (Irish Branch)
2nd Floor, Building 10,
Cherrywood Business Park,
Loughlinstown,
Co. Dublin,
IE – Dublin D18 T3Y1
Tel: +353 (0) 1 256 9800

17. Other information

The vaccine contains an inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 ORF2 protein. It is intended to stimulate active immunity against PCV2 in pigs.